Biosynth have, together with the Swiss company Solvias AG, finished the first phase of upscaling of the syntetic anthocyanin molecules. Solvias is a wold leader in contract research development and upscaling (CRO/CDMO).

The process will be imlemented at the new facility at Foss Eikeland.